Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Oct. 21:Verastem, Inc. (VSTM) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 21.5% over the last 60 days.Verastem’s shares gained 52.2% over the last three months compared with the S&P 500’s advance of 5.7%. The company possesses a Momentum Score  of A.Amer Sports, Inc. (AS) : This sports and outdoor brands company ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Newmont Corporation (NEM) : This producer and explorer of gold and other metals has seen the Zacks Consensus Estimate for its current year earnings increasing 6.9% over the last 60 days.Royal Bank of Canada (RY) : This diversified financial services company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.Amer Sports, Inc. (AS) : This sports and outdoor brands company has seen the ...

公司业务进展 - 公司与GenFleet Therapeutics合作开发GFH375 (VS-7375) 用于治疗晚期KRAS G12D突变胰腺导管腺癌 旨在为治疗选择有限的患者提供新方案 可能改变治疗格局 [1][4] - GFH375针对的是具有挑战性的癌症突变 其潜在成功可能提升公司的市场地位和财务前景 [1][4] 市场评级与股价表现 - RBC Capital维持对公司"跑赢大盘"评级 尽管公司市盈率为负3.38倍 当前股价为8.32美元 [2] - RBC Capital给出的目标价为13美元 暗示股价有62.3%的上涨潜力 反映了对其战略举措和潜在突破的信心 [2][5] 财务状况分析 - 公司企业价值与经营现金流比率为负3.62倍 显示其产生正现金流存在困难 [3] - 公司流动比率为3.46 表明其偿付短期负债能力强 [3] - 公司负债权益比为2.09 显示其负债多于权益 [4]

公司概况与投资主题 - 公司是一家专注于研发和商业化改善癌症患者生活药物的生物制药公司 [1] - 公司近期在投资界受到关注，尤其对动量投资者具有吸引力 [1] - 动量投资策略关注显示上涨趋势且预期趋势将持续的股票 [1] 分析师评级与价格目标 - 2025年10月20日，RBC Capital设定目标价为13美元，当时股价8.01美元，隐含62.3%上涨潜力 [2] - 分析师设定的平均目标价为15.5美元，隐含68.1%的上涨潜力 [3] - 华尔街分析师给出的目标价范围在13美元至20美元之间，隐含41%至116.9%的上涨潜力 [5] - 目标价的标准差为2.62美元，表明分析师间存在适度分歧 [5] 股价表现与动量评分 - 公司获得Zacks投资研究的动量风格评分A级，表明持续积极表现的潜力强劲 [3] - 当前股价为9.22美元，过去四周上涨1.9% [3] - 近期股价下跌7.97%至8.49美元，当日交易区间为6.98美元至9.02美元 [4] - 过去52周股价区间为2.95美元低点至11.25美元高点 [4] 市场数据与估值 - 公司当前市值约为5.222亿美元 [4] - 在纳斯达克交易所的成交量为4,762,954股 [4] - RBC Capital认为公司的数据属于"同类最佳"，可能推动未来增长 [2]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

Verastem (VSTM) closed the last trading session at $9.22, gaining 1.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.5 indicates a 68.1% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $2.62. While the lowest estimate of $13.00 indicates a 41% increase from the current price level, the most optimistic analyst expects th ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and safety data from partner GenFleet Therapeutics' Phase 1/2 monotherapy study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor (VS-7375 outside of China) for patients with KRAS G12D mutant advanced pancreatic ductal adenocarcinoma (PDAC). Among 59 heavily pre-treated pat. ...

I have found a lot of things to be optimistic about with respect to the Verastem (NASDAQ: VSTM ) investment thesis in past articles, including my most recent one focusingI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosur ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 138,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c. ...

Verastem (VSTM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...